Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?

참고문헌 (9)

1. Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
2. Li M, "Systematic review with meta-analysis : vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori", Helicobacter, 23, pp.e12495~ (2018)
3. Kato M, "Guidelines for the management of Helicobacter pylori infection in Japan : 2016 revised edition", Helicobacter, 24, pp.e12597~ (2019)
4. Jung Yoon Suk, "Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study", Gut and Liver, 17(5), pp.711~721 (2023), 거트앤리버 소화기연관학회협의회[DOI]
5. Graham DY, "A report card to grade Helicobacter pylori therapy", Helicobacter, 12, pp.275~278 (2007)
6. Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
7. Choi Yoon Jin, "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial", Gut and Liver, 16(4), pp.535~546 (2022), 거트앤리버 소화기연관학회협의회[DOI]
8. Horikawa C, "High risk of failing eradication of Helicobacter pylori in patients with diabetes : a meta-analysis", Diabetes Res Clin Pract, 106, pp.81~87 (2014)
9. Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection : the Maastricht III Consensus Report", Gut, 56, pp.772~781 (2007)

관련 논문AI추천